Consequently, in ER+ tumors, high expression of JMJD6 may allow breast cancer cell proliferation by alternate means, in the absence of E2 or when blockade of the E2-ER axis occurs during endocrine therapy. Here, JMJD6 is linked to breast carcinoma.